[go: up one dir, main page]

ES2115611T3 - Gen suprimido en el cancer colorrectal humano. - Google Patents

Gen suprimido en el cancer colorrectal humano.

Info

Publication number
ES2115611T3
ES2115611T3 ES91902391T ES91902391T ES2115611T3 ES 2115611 T3 ES2115611 T3 ES 2115611T3 ES 91902391 T ES91902391 T ES 91902391T ES 91902391 T ES91902391 T ES 91902391T ES 2115611 T3 ES2115611 T3 ES 2115611T3
Authority
ES
Spain
Prior art keywords
dcc
gene
colorectal cancer
human
human colorectal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91902391T
Other languages
English (en)
Inventor
Bert Vogelstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of ES2115611T3 publication Critical patent/ES2115611T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/57535—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

GEN ANULADO EN EL CANCER COLORRECTAL DE SERES HUMANOS SE PRESENTA UN NUEVO GEN HUMANO DENOMINADO DCC. LOS METODOS Y KITS PARA LLEVAR A CABO LAS MUTACIONES DEL GEN DCC EN LOS TEJIDOS HUMANOS Y EN MUESTRAS DEL CUERPO HUMANO. LA INSERCION, ANULACION Y MUTACIONES PUNTUALES EN EL DCC SE OBSERVAN EN LAS CELULAS TUMORALES HUMANAS. LOS TEJIDOS NORMALES EXPRESAN EL DCC MIENTRAS QUE LA MAYORIA DE LOS CANCERES COLORRECTALES NO LO HACEN. LA PERDIDA DE GENES DCC DE TIPO SALVAJE ESTA RELACIONADA CON LA PROGRESION NEOPLASTICA Y UNA ESPERANZA DE VIDA DISMINUIDA.
ES91902391T 1990-01-04 1990-12-19 Gen suprimido en el cancer colorrectal humano. Expired - Lifetime ES2115611T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46098190A 1990-01-04 1990-01-04

Publications (1)

Publication Number Publication Date
ES2115611T3 true ES2115611T3 (es) 1998-07-01

Family

ID=23830791

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91902391T Expired - Lifetime ES2115611T3 (es) 1990-01-04 1990-12-19 Gen suprimido en el cancer colorrectal humano.

Country Status (10)

Country Link
US (5) US5532108A (es)
EP (1) EP0507852B1 (es)
JP (1) JPH05508307A (es)
AT (1) ATE164629T1 (es)
AU (1) AU649431B2 (es)
CA (1) CA2073186C (es)
DE (1) DE69032209T2 (es)
DK (1) DK0507852T3 (es)
ES (1) ES2115611T3 (es)
WO (1) WO1991009964A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9201929D0 (sv) * 1992-06-23 1992-06-23 Pharmacia Lkb Biotech Method and system for molecular-biological diagnostics
JP3151054B2 (ja) * 1992-06-25 2001-04-03 協和醗酵工業株式会社 抗ｄｃｃ遺伝子産物モノクローナル抗体
AU6350894A (en) * 1993-03-05 1994-09-26 Clifford W. Schweinfest Colon mucosa gene having down-regulated expression in colon adenomas and adenocarcinomas
JPH09501045A (ja) * 1993-05-26 1997-02-04 ザ・ジョーンズ・ホプキンス・ユニバーシティ Ｄｃｃ遺伝子産物特異的抗体
US5709998A (en) * 1993-12-15 1998-01-20 The Johns Hopkins University Molecular diagnosis of familial adenomatous polyposis
CH686982A5 (fr) * 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
US5753441A (en) * 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
ES2164136T5 (es) * 1994-08-12 2009-02-16 The University Of Utah Research Foundation Sondas de acidos nucleicos que copmrenden un fragmento del gen de susceptibilidad al cancer de mama y ovarios asociado a 17q.
US5747282A (en) * 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
US5693473A (en) * 1994-08-12 1997-12-02 Myriad Genetics, Inc. Linked breast and ovarian cancer susceptibility gene
US5709999A (en) * 1994-08-12 1998-01-20 Myriad Genetics Inc. Linked breast and ovarian cancer susceptibility gene
US5702886A (en) * 1994-10-05 1997-12-30 The Johns Hopkins University Chromosome I8Q loss and prognosis in colorectal cancer
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5891629A (en) * 1995-09-28 1999-04-06 Ambion, Inc. Compositions for improving RNase cleavage of base pair mismatches in double-stranded nucleic acids
GB9518156D0 (en) * 1995-09-06 1995-11-08 Medical Res Council Method of isolating cells
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
EP1291657A3 (en) * 1996-01-30 2003-08-27 Exact Sciences Corporation Methods for detecting colon cancer from stool samples
AU736301B2 (en) * 1996-05-01 2001-07-26 Imarx Therapeutics, Inc. Methods for delivering compounds into a cell
US5858665A (en) * 1996-07-25 1999-01-12 Navix, Inc. Homogeneous diagnostic assay method utilizing simultaneous target and signal amplification
US6146828A (en) * 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6100029A (en) * 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US5928870A (en) * 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6300077B1 (en) 1996-08-14 2001-10-09 Exact Sciences Corporation Methods for the detection of nucleic acids
US6020137A (en) * 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US5830665A (en) * 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6406857B1 (en) 1997-06-16 2002-06-18 Exact Sciences Corporation Methods for stool sample preparation
US6268136B1 (en) 1997-06-16 2001-07-31 Exact Science Corporation Methods for stool sample preparation
US20020064792A1 (en) * 1997-11-13 2002-05-30 Lincoln Stephen E. Database for storage and analysis of full-length sequences
US6280947B1 (en) 1999-08-11 2001-08-28 Exact Sciences Corporation Methods for detecting nucleotide insertion or deletion using primer extension
US6503718B2 (en) 1999-01-10 2003-01-07 Exact Sciences Corporation Methods for detecting mutations using primer extension for detecting disease
ATE272844T1 (de) * 1999-01-14 2004-08-15 Ca Immunoassays zum nachweis von krankheiten oder krankheitsanfälligkeitsmerkmalen
US7148016B1 (en) 1999-01-14 2006-12-12 Ca*Tx Inc. Immunoassays to detect diseases or disease susceptibility traits
US6551777B1 (en) 1999-02-25 2003-04-22 Exact Sciences Corporation Methods for preserving DNA integrity
JP4794052B2 (ja) 1999-04-09 2011-10-12 ジェンザイム・コーポレーション 癌の指標である核酸を検出するための方法
US6849403B1 (en) 1999-09-08 2005-02-01 Exact Sciences Corporation Apparatus and method for drug screening
US6586177B1 (en) * 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
US6919174B1 (en) 1999-12-07 2005-07-19 Exact Sciences Corporation Methods for disease detection
WO2001042781A2 (en) * 1999-12-07 2001-06-14 Exact Sciences Corporation Supracolonic aerodigestive neoplasm detection
AU2001260116A1 (en) * 2000-03-14 2001-09-24 Bayer Aktiengesellschaft Human dcc-like proteins
US6492120B1 (en) 2000-11-02 2002-12-10 University Of Maryland Nucleic acid hybridization assay utilizing tricyclic target and signal amplification
US6428964B1 (en) 2001-03-15 2002-08-06 Exact Sciences Corporation Method for alteration detection
CA2464608A1 (en) * 2001-10-25 2003-05-01 The Hospital For Sick Children Method for williams-beuren syndrome diagnosis
US7776524B2 (en) * 2002-02-15 2010-08-17 Genzyme Corporation Methods for analysis of molecular events
WO2004090547A2 (en) * 2003-04-04 2004-10-21 Protein Design Labs, Inc. Metastatic colorectal cancer signatures
US20040259101A1 (en) * 2003-06-20 2004-12-23 Shuber Anthony P. Methods for disease screening
JP2007512509A (ja) * 2003-11-05 2007-05-17 エグザクト サイエンシーズ コーポレイション 反復的親和性分離およびその使用
US20080241827A1 (en) * 2004-05-10 2008-10-02 Exact Sciences Corporation Methods For Detecting A Mutant Nucleic Acid
WO2005113769A1 (en) * 2004-05-14 2005-12-01 Exact Sciences Corporation Method for stabilizing biological samples for nucleic acid analysis
US7981607B2 (en) * 2004-08-27 2011-07-19 Esoterix Genetic Laboratories LLC Method for detecting recombinant event
WO2006047787A2 (en) 2004-10-27 2006-05-04 Exact Sciences Corporation Method for monitoring disease progression or recurrence
ATE406463T1 (de) 2005-04-06 2008-09-15 Maurice Stroun Methode zur krebsdiagnose mittels nachweis von dna und rna im kreislauf
US9777314B2 (en) 2005-04-21 2017-10-03 Esoterix Genetic Laboratories, Llc Analysis of heterogeneous nucleic acid samples
EP2971091A1 (en) 2013-03-14 2016-01-20 Abbott Molecular Inc. Materials and methods for assessment of colorectal adenoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831124A (en) * 1980-12-10 1989-05-16 Research Corporation Technologies Recombinant cDNA construction method and hybrid nucleotides useful in cloning
US5380645A (en) * 1989-03-16 1995-01-10 The Johns Hopkins University Generalized method for assessment of colorectal carcinoma
US5043272A (en) * 1989-04-27 1991-08-27 Life Technologies, Incorporated Amplification of nucleic acid sequences using oligonucleotides of random sequence as primers
JP3151054B2 (ja) * 1992-06-25 2001-04-03 協和醗酵工業株式会社 抗ｄｃｃ遺伝子産物モノクローナル抗体

Also Published As

Publication number Publication date
US5532108A (en) 1996-07-02
DE69032209T2 (de) 1998-12-03
EP0507852A1 (en) 1992-10-14
CA2073186A1 (en) 1991-07-05
EP0507852B1 (en) 1998-04-01
EP0507852A4 (en) 1993-04-28
ATE164629T1 (de) 1998-04-15
US5650281A (en) 1997-07-22
US5602243A (en) 1997-02-11
JPH05508307A (ja) 1993-11-25
US5561223A (en) 1996-10-01
AU649431B2 (en) 1994-05-26
US5874545A (en) 1999-02-23
WO1991009964A1 (en) 1991-07-11
CA2073186C (en) 2002-06-11
AU7158591A (en) 1991-07-24
DE69032209D1 (de) 1998-05-07
DK0507852T3 (da) 1999-01-04

Similar Documents

Publication Publication Date Title
ES2115611T3 (es) Gen suprimido en el cancer colorrectal humano.
ATE194660T1 (de) Veraendertes gen bei menschlichem colorektalem- krebs
CY1107778T1 (el) Ανθρωπινα cd45+ ή/και ινοβλαστης + μεσεγχυματικα βλαστικα κυτταρα
ES2634546T3 (es) Uso de células madre mesenquimales modificadas genéticamente para expresar un gen suicida para tratar un cáncer
ES2195664T3 (es) Uso de fumaratos de dialquilo.
Endo et al. Clinical studies of early gastric cancer
DE69907155D1 (de) Krebsbehandlung
EP0390323A3 (en) Detection of loss of the wild-type p53 gene
ZA200108258B (en) Methods of inducing cancer cell death and tumor regression.
WO2004079368A3 (en) Markers for colorectal cancer
ATE237371T1 (de) Blasenmukosa mit zellen für die rekonstruktion von geweben
NO20002979D0 (no) Undersøkelse av human papillomavirus-relatert sykdom
TR199801395A2 (xx) Genetik olarak de�i�tirilmi� h�creler ve bunlar�n kullan�mlar�.
DE60109437D1 (de) Mehrteiliges vaginales zylindersystem zur niedrigdosierten brachytherapie
CY1108798T1 (el) To μονοξειδιο toy ανθρακα βελτιωνει τα αποτελεσματα στις μεταμοσχευσεις ιστου και οργανων και καταστελει την αποπτωση
ES489204A1 (es) Elemento destinado a implantarse en tejido corporal, parti- cularmente tejido oseo
CY1110029T1 (el) Γονιδιο που εκφραζεται στον καρκινο του προστατη
DE60032784D1 (de) Markerproteine für prostatakrebs
MXPA03003011A (es) Metodos para inducir muerte de celulas cancerosas y regresion de tumores.
FR2440183A1 (fr) Endoscope
ATE287734T1 (de) Radionukleiide assoziierte nukleotid- polyphosphate zur bilddarstellung von tumoren
DE60016429D1 (de) Zell- und/oder tumor-spezifische promotor-abhängige änderung der gezielten expression des herpes gamma 34.5 gens
CY1105572T1 (el) Φωσφολιπιδικοι εστερες κλοφαραβινης
ES2183752T1 (es) Vectores adenovirales recombinantes y su utilizacion en el tratamiento de distintos tipos de la fibrosis hepatica, renal y pulmonar y cicatrices hipertroficas.
ES2185472A1 (es) Empleo del gen slug, o de sus productos de transcripcion o expresion, en la deteccion y/o tratamiento de celulas cancerosas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 507852

Country of ref document: ES